Vnitřní lékařství 1/2021

DIFERENCIÁLNĚ-DIAGNOSTICKÉ OKÉNKO ANEB NA CO SE VÁS MOHOU ZEPTAT U ATESTACE Horečka nejasného původu E42 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék 2021; 67(1): e32–e42 / www.casopisvnitrnilekarstvi.cz 14. Mackowiak PA, Durack DT. Fever of unknown origin. In: Bennett JE, Dolin R, Blaser MJ, Parta M (eds). Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Disea- ses. 8th ed. Elsevier Saunders: Philadelphia 2015: 721–729. 15. Bottieau E, Clerinx J, Van den Enden E, et al. Fever after a stay in the tropics: diagnos- tic predictors of the leading tropical conditions. Medicine (Baltimore) 2007; 86(1): 18–25. 16. Zenone T. Fever of unknown origin in rheumatic diseases. Infect Dis Clin North Am 2007; 21(4): 1115–1135. 17. Gerfaud‑Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult‑onset Still’s disease. Autoimmun Rev 2014; 13(7): 708–722. 18. Foggo V, Cavenagh J. Malignant causes of fever of unknown origin. Clin Med (Lond) 2015; 15(3): 292–294. 19. Chang JC, Gross HM. Utility of naproxen in the differential diagnosis of fever of unde- termined origin in patients with cancer. Am J Med 1984; 76: 597–603. 20. Roush MK, Nelson KM. Understanding drug‑induced febrile reactions. Am Pharm 1993; 33(10): 39–42. 21. Mackowiak PA. Drug fever: mechanisms, maxims and misconceptions. Am J Med Sci. 1987; 294(4): 275–286. 22. Ochi H, Wada K, Okada H, et al. The persistence of drug‑induced fever by teicoplanin- --a case report. Int J Clin Pharmacol Ther. 2011; 49(5): 339–343. 23. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331(19): 1272–1285. 24. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol 2013; 68(5): 693.e1–e14. 25. Cunha BA. Fever of unknown origin: focused diagnostic approach based on clinical clues from the history, physical examination, and laboratory tests. Infect Dis Clin North Am 2007; 21(4): 1137–1187. 26. Kovačevičová M, Švestková S. Retikulární exantémy – patofyziologie, etiopatogeneze, klasifikace. Čes‑slov Derm 2012; 87(6): 211–219. 27. Fogo A, du Vivier A. The cutaneous manifestations of haematological malignancy. Clin Med (Lond) 2009; 9(4): 366–370. 28. Shmerling RH. Evaluation of the adult with polyarticular pain. UpToDate 2020. [cit. 2020-06-25]. Dostupné z www: <https://www.uptodate.com/contents/evaluation‑of­ ‑the‑adult‑with‑polyarticular‑pain>. 29. Gaddey HL, Riegel AM. Unexplained Lymphadenopathy: Evaluation and Differential Diagnosis. Am Fam Physician 2016; 94(11): 896–903. 30. Bona R. Evaluation of splenomegaly and other splenic disorders in adults. UpToDa- te 2020. [cit. 2020-06-25]. Dostupné z www: <https://www.uptodate.com/contents/ evaluation‑of‑splenomegaly‑and‑other‑splenic‑disorders‑in‑adults>. 31. Curry MP, Bonder A. Overwiew of the evaluation of hepatomegaly in adults. UpToDa- te. 2020 [cited 2020 Jun 25]. Dostupné z www: <https://www.uptodate.com/contents/ overview‑of‑the‑evaluation‑of‑hepatomegaly‑in‑adults>. 32. Loughrey PB, Armstrong D, Lockhart CJ. Classical eye signs in bacterial endocarditis. QJM 2015; 108(11): 909–910. 33. Ruddy SM, Bergstrom R, Tivakaran VS. Roth Spots. StatPearls 2020. [cit. 2020-06-25]. Dostupné z www: <https://www.ncbi.nlm.nih.gov/books/NBK482446/>. 34. Shane E. Diagnostic approach to hypercalcemia. UpToDate 2020. [cit. 2020-07-12]. Dostup- né z www: < https://www.uptodate.com/contents/diagnostic‑approach‑to‑hypercalcemia>. 35. Bray C, Bell LN, Liang H, et al . Erythrocyte Sedimentation Rate and C‑reacti- ve Protein Measurements and Their Relevance in Clinical Medicine. WMJ 2016; 115(6): 317–321. 36. Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C‑reactive protein levels as markers of bacterial infection: a systematic review and meta‑analysis. Clin Infect Dis 2004; 39(2): 206–217. 37. Maruna P. Proteiny akutní fáze. 1. vydání. Maxdorf: Praha 2004. 38. Erez A, Shental O, Tchebiner JZ, et al. Diagnostic and prognostic value of very high serum lactate dehydrogenase in admitted medical patients. Isr Med Assoc J 2014; 16(7): 439–443. 39. Li L, Dong M, Wang XG. The Implication and Significance of Beta 2 Microglobulin: A Con- servative Multifunctional Regulator. Chin Med J (Engl) 2016; 129(4): 448–455. 40. Castro C, Gourley M. Diagnostic testing and interpretation of tests for autoimmunity. J Allergy Clin Immunol 2010; 125(Suppl 2): S238–S247. 41. Dasgupta A, Wahed A. Protein Electrophoresis and Immunofixation. In Dasgupta A, Wahed A (authors). Clinical chemistry, immunology and laboratory quality control: A com- prehensive review for board preparation, certification and clinical practice. 1st ed. Else- vier: Amsterdam 2014: 391–405. 42. Casulo C, Maragulia J, Zelenetz AD. Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infecti- ons. Clin Lymphoma Myeloma Leuk 2013; 13(2): 106–111. 43. De Angelis F, Tosti ME, Capria S, et al. Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non‑Hodgkin lymphomas: A retrospective cohort study. Leuk Res 2015; 39(12): 1382–1388. 44. Guyomard S, Salles G, Coudurier M et al. Prevalence and pattern of antinuclear autoantibodies in 347 patients with non-Hodgkin’s lymphoma. Br J Haematol 2003; 123(1): 90–99. 45. Coburn B, Morris AM, Tomlinson G, et al. Does this adult patient with suspected bac- teremia require blood cultures? JAMA 2012; 308(5): 502–511. 46. Werner M, Andersson R, Olaison L, et al. A clinical study of culture‑negative endocar- ditis. Medicine (Baltimore) 2003; 82(4): 263–273. 47. Dibble EH, Yoo DC, Noto RB. Role of PET/CT in Workup of Fever without a Source. Ra- diographics 2016; 36(4): 1166–1177. 48. Vilacosta I, Olmos C, de Agustín A, et al. The diagnostic ability of echocardiography for infective endocarditis and its associated complications. Expert Rev Cardiovasc Ther 2015; 13(11): 1225–1236. 49. Censullo A, Vijayan T. Using Nuclear Medicine Imaging Wisely in Diagnosing Infec- tious Diseases. Open Forum Infect Dis 2017; 4(1): ofx011. Dostupné z DOI: <https://doi. org/10.1093/ofid/ofx011>. 50. Hung BT, Wang PW, Su YJ, et al. The efficacy of 18 F‑FDG PET/CT and 67Ga SPECT/CT in diagnosing fever of unknown origin. Int J Infect Dis 2017; 62: 10–17. 51. Seshadri N, Sonoda LI, Lever AM, et al. Superiority of 18 F‑FDGPET compared to 111In‑labelled leucocyte scintigraphy in the evaluation of fever of unknown origin. J Infect 2012; 65(1): 71–79. 52. Roth AR, Basello GM. Approach to the adult patient with fever of unknown origin. Am Fam Physician 2003; 68(11): 2223–2228. 53. Tan Y, Liu X, Shi X. Clinical features and outcomes of patients with fever of unknown origin: a retrospective study. BMC Infect Dis 2019; 19(1): 198.